Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. PREVALENCE OF SARS-COV-2-ANTIBODIES IN DANISH CHILDREN AND ADULTS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A qualitative study of adolescent cancer survivors perspectives on social support from healthy peers - A RESPECT study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. National, clinical cohort study of late effects among survivors of acute lymphoblastic leukaemia: the ALL-STAR study protocol

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • S Modvig
  • H Hallböök
  • H O Madsen
  • S Siitonen
  • S Rosthøj
  • A Tierens
  • V Juvonen
  • L T N Osnes
  • H Vålerhaugen
  • M Hultdin
  • R Matuzeviciene
  • M Stoskus
  • M Marincevic
  • A Lilleorg
  • M Ehinger
  • U Norén-Nystrøm
  • N Toft
  • M Taskinen
  • O G Jónsson
  • K Pruunsild
  • G Vaitkeviciene
  • K Vettenranta
  • B Lund
  • J Abrahamsson
  • A Porwit
  • K Schmiegelow
  • H V Marquart
Vis graf over relationer

PCR of TCR/Ig gene rearrangements is considered the method of choice for minimal residual disease (MRD) quantification in BCP-ALL, but flow cytometry analysis of leukemia-associated immunophenotypes (FCM-MRD) is faster and biologically more informative. FCM-MRD performed in 18 laboratories across seven countries was used for risk stratification of 1487 patients with BCP-ALL enrolled in the NOPHO ALL2008 protocol. When no informative FCM-marker was available, risk stratification was based on real-time quantitative PCR. An informative FCM-marker was found in 96.2% and only two patients (0.14%) had non-informative FCM and non-informative PCR-markers. The overall 5-year event-free survival was 86.1% with a cumulative incidence of relapse (CIR5y) of 9.5%. FCM-MRD levels on days 15 (HzR 4.0, p < 0.0001), 29 (HzR 2.7, p < 0.0001), and 79 (HzR 3.5, p < 0.0001) associated with hazard of relapse adjusted for age, cytogenetics, and WBC. The early (day 15) response associated with CIR5y adjusted for day 29 FCM-MRD, with higher levels in adults (median 2.4 × 10-2 versus 5.2 × 10-3, p < 0.0001). Undetectable FCM- and/or PCR-MRD on day 29 identified patients with a very good outcome (CIR5y = 3.2%). For patients who did not undergo transplantation, day 79 FCM-MRD > 10-4 associated with a CIR5y = 22.1%. In conclusion, FCM-MRD performed in a multicenter setting is a clinically useful method for MRD-based treatment stratification in BCP-ALL.

OriginalsprogEngelsk
TidsskriftLeukemia
ISSN0887-6924
DOI
StatusE-pub ahead of print - 2021

ID: 61784243